Biogen study shows long-term benefits of haemophilia B therapy Alprolix

Biogen has announced positive findings from a new study that demonstrates the long-term benefits offered by its haemophilia B therapy Alprolix.

The phase III open-label extension study B-YOND has supported the long-term safety and efficacy of the drug in people with severe haemophilia B treated for up to two years.

Participants in the study maintained low bleeding rates with one to two week prophylaxis regimens, according to data from an interim analysis, with benefits shown for adult, adolescent and paediatric patients.

Alprolix is a recombinant clotting factor IX therapy designed to have prolonged circulation in the body. To date, it has been approved in the US, Canada, Australia and Japan.

Dr Amy Shapiro, co-founder and medical director of the Indiana Hemophilia and Thrombosis Center, said: "We believe B-YOND will play an important role in helping us understand this therapy's clinical profile over the long term."

The therapy was accepted for regulatory review by the European Medicines Agency earlier this year.